CJC-1295 Pharmacokinetics & Safety RCT Findings
A randomized trial found CJC-1295 produced sustained, dose-dependent GH and IGF-1 increases in healthy adults with an estimated half-life of 5.8–8.1 days.
A randomized trial found CJC-1295 produced sustained, dose-dependent GH and IGF-1 increases in healthy adults with an estimated half-life of 5.8–8.1 days.